1. **(Canceled)**

2. **(Currently Amended)** A compound of Formula I

A - D - B (I)

or a pharmaceutically acceptable salt thereof, wherein:

D is -NH-C(O)-NH-,

A is of the formula: -L-(M-$L^1$)$_q$, where

L is substituted or unsubstituted phenyl bound directly to D,

$L^1$ is phenyl substituted by -C(O)$R_x$, pyridinyl substituted by -C(O)$R_x$, or isoindoline ~~a 5 to 6 membered hetaryl moiety substituted by at least one substituent, -C(O)$R_x$, wherein the heteroatoms of said hetaryl moiety consist of nitrogen~~,

M is oxygen,

q is 1 and

B is a substituted or unsubstituted pyridyl group, a substituted or unsubstituted quinolinyl group or a substituted or unsubstituted isoquinolinyl group,

where B is substituted, L is substituted or $L^1$ is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and Wn, where n is 0-3;

$R_x$ is $NR_aR_b$ where $R_a$ and $R_b$ are,

a) independently hydrogen, $C_1$-$C_{10}$ alkyl, ~~$C_1$-$C_{10}$ alkoxy,~~ $C_{3-10}$ cycloalkyl, $C_{2-10}$ alkenyl, $C_{1-10}$ alkenoyl, phenyl, pyridinyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, tetrahydrofuryl, substituted $C_{1-10}$ alkyl, substituted $C_{3-10}$ cycloalkyl, substituted phenyl, substituted pyridinyl, substituted piperazinyl, substituted morpholinyl, substituted piperidinyl, substituted pyrrolidinyl, or substituted tetrahydrofuryl, ~~$C_{6-12}$ aryl, $C_{3-12}$ hetaryl which is a 5-12 carbon atom aromatic ring system of 1-3 rings, at least one of which is aromatic, in which 1-3 carbon atoms are replaced by heteroatoms selected from O, N and S, 5-6 membered $C_{3-12}$ cycloalkyl having 0-3 heteroatoms selected from N, S and O, substituted $C_{1-10}$ alkyl, substituted $C_{1-10}$ alkoxy, substituted 5-6 membered $C_{3-10}$ cycloalkyl, having 0-3 heteroatoms selected from N, S and O, substituted $C_{6-12}$ aryl, substituted $C_{3-12}$ hetaryl which is a 5-12 carbon atom aromatic ring system of 1-3 rings, at least one of which is~~

~~aromatic, in which 1-3 carbon atoms are replaced by heteroatoms selected from N, S and O,~~ where $R_a$ and $R_b$ are a substituted group, they are substituted by halogen up to per halo, hydroxy, $C_{1-10}$ alkyl, $C_{1-10}$ alkoxy, $C_{3-10}$ cycloalkyl, phenyl, pyridinyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, tetrahydrofuryl, ~~5-6 membered $C_{3-12}$ cycloalkyl having 0-3 heteroatoms selected from O, S and N, $C_{3-12}$ hetaryl which is a 5-12 carbon atom aromatic ring system of 1-3 rings, at least one of which is aromatic, in which 1-3 carbon atoms are replaced by heteroatoms selected from N, S and O, $C_{1-10}$ alkoxy, $C_{6-12}$ aryl,~~ halo-substituted $C_{1-6}$ alkyl up to per halo alkyl, ~~halo-substituted $C_6$-$C_{12}$ aryl up to per halo aryl, halo-substituted 5-6 membered $C_3$-$C_{12}$ cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo-substituted $C_3$-$C_{12}$ hetaryl which is a 5-12 carbon atom aromatic ring system of 1-3 rings, at least one of which is aromatic, in which 1-3 carbon atoms are replaced by heteroatoms selected from N, S and O, up to per halo hetaryl;~~ halo-substituted phenyl up to per halo phenyl, halo-substituted pyridinyl, up to per halo pyridinyl, halo-substituted morpholinyl, up to per halo morpholinyl, halo-substituted piperidinyl, up to per halo piperidinyl, halo-substituted pyrrolidinyl, up to per halo pyrrolidinyl, or halo-substituted tetrahydrofuryl up to per halo tetrahydrofuryl,

each W is independently -CN, $-CO_2R^7$, $-C(O)NR^7R^7$, $-C(O)-R^7$, $-NO_2$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, $C_1$-$C_{10}$ alkyl, $C_1$-$C_{10}$ alkoxy, $C_2$-$C_{10}$ alkenyl, $C_1$-$C_{10}$ alkenoyl, $C_3$-$C_{10}$ cycloalkyl, phenyl, pyridinyl, pyrazolyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, or tetrahydrofuryl, ~~$C_6$-$C_{14}$ aryl, $C_{3-12}$ hetaryl which is a 5-12 carbon atom aromatic ring system of 1-3 rings, at least one of which is aromatic, in which 1-3 carbon atoms are replaced by heteroatoms selected from O, N and S,~~ substituted $C_1$-$C_{10}$ alkyl, substituted $C_1$-$C_{10}$ alkoxy, substituted $C_2$-$C_{10}$ alkenyl, substituted $C_1$-$C_{10}$ alkenoyl, substituted $C_3$-$C_{10}$ cycloalkyl substituted phenyl, substituted pyridinyl, substituted pyrazolyl substituted piperazinyl, substituted morpholinyl, substituted piperidinyl, substituted pyrrolidinyl, or substituted tetrahydrofuryl, ~~substituted $C_6$-$C_{12}$ aryl or substituted $C_3$-$C_{12}$ hetaryl which is a 5-12 carbon atom aromatic ring system of 1-3 rings, at least one of which is~~

~~aromatic, in which 1-3 carbon atoms are replaced by heteroatoms selected from O, N and S~~;

where W is a substituted group, it is substituted by one or more substituents which are each, independently, -CN, $-CO_2R^7$, $-C(O)R^7$, $-C(O)NR^7R^7$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NO_2$, $-NR^7C(O)R^7$, $-NR^7C(O)OR^7$ or halogen,

each $R^7$ is independently H, $C_1$-$C_{10}$ alkyl, $C_1$-$C_{10}$ alkoxy, $C_2$-$C_{10}$ alkenyl, $C_1$-$C_{10}$ alkenoyl, $C_3$-$C_{10}$ cycloalkyl, phenyl or pyridinyl ~~$C_6$-$C_{14}$ aryl, $C_3$-$C_{12}$ hetaryl which is a 5-12 carbon atom aromatic ring system of 1-3 rings, at least one of which is aromatic, in which 1-3 carbon atoms are replaced by heteroatoms selected from O, N and S,~~ up to per-halosubstituted pyridinyl, ~~$C_3$-$C_{12}$ hetaryl which is a 5-12 carbon atom aromatic ring system of 1-3 rings, at least one of which is aromatic, in which 1-3 carbon atoms are replaced by heteroatoms selected from O, N and S,~~ up to per-halosubstituted $C_1$-$C_{10}$ alkyl, up to per-halosubstituted $C_3$-$C_{10}$ cycloalkyl or up to per-halosubstituted phenyl ~~$C_6$-$C_{14}$ aryl~~.

**3.** **(Previously Presented)** A compound as in claim 2 wherein L' is phenyl or pyridinyl.

**4.** **(Previously Presented)** A compound as in claim 2 wherein the cyclic structures of B and L bound directly to D are substituted in the ortho position by hydrogen.

**5.** **(Previously Presented)** A compound of claim 2 wherein B of Formula I is a substituted pyridyl, substituted quinolinyl or substituted isoquinolinyl group substituted 1 to 3 times by one or more substituents which are each, independently, -CN, halogen, $C_1$-$C_{10}$ alkyl, $C_1$-$C_{10}$ alkoxy, -OH, up to per halo substituted $C_1$-$C_{10}$ alkyl, up to per halo substituted $C_1$-$C_{10}$ alkoxy or phenyl substituted by halogen up to per halo.

**6.** **(Canceled)**

7. **(Canceled)**

8. **(Canceled)**

9. **(Currently amended)** A compound of claim 2, wherein $L^1$ is phenyl or pyridinyl ~~, pyridinyl or pyrimidinyl~~.

10. **(Currently amended)** A compound of claim 5, wherein $L^1$ is phenyl or pyridinyl ~~, pyridinyl or pyrimidinyl~~.

11. **(Canceled)**

12. **(Previously Presented)** A compound of claim 2 wherein $L^1$ is additionally substituted 1 to 3 times by one or more substituents which are each, independently, $C_1$-$C_{10}$ alkyl, up to per halo substituted $C_1$-$C_{10}$ alkyl, -CN, -OH, halogen, $C_1$-$C_{10}$ alkoxy or up to per halo substituted $C_1$-$C_{10}$ alkoxy.

13. **(Canceled)**

14. **(Previously Presented)** A compound of claim 10 wherein $L^1$ is additionally substituted 1 to 3 times by one or more substituents which are each, independently, $C_1$-$C_{10}$ alkyl, up to per halo substituted $C_1$-$C_{10}$ alkyl, -CN, -OH, halogen, $C_1$-$C_{10}$ alkoxy or up to per halo substituted $C_1$-$C_{10}$ alkoxy.

15. **(Previously Presented)** A compound of claim 2 wherein $L^1$ is substituted only by $-C(O)R_x$.

16. **(Previously Presented)** A compound of claim 2 wherein $L^1$ is substituted by $-C(O)R_x$ wherein $R_x$ is $NR_aR_b$ and $R_a$ and $R_b$ are independently hydrogen or $C_1$ - $C_{10}$ alkyl.

17. **(Previously presented)** A compound of claim 3 wherein $L^1$ is substituted by $-C(O)R_x$, wherein $R_x$ is $NR_aR_b$ and $R_a$ and $R_b$ are independently hydrogen or $C_1$ - $C_{10}$ alkyl .

18. **(Previously presented)** A compound of claim 10 wherein $L^1$ is substituted by $-C(O)R_x$, wherein $R_x$ is $NR_aR_b$ and $R_a$ and $R_a$ are independently hydrogen or $C_1$ - $C_{10}$ alkyl .

19. **(Canceled)**

20. **(Canceled)**

21. **(Canceled)**

22. **(Canceled)**

23. **(Canceled)**

24. **(Canceled)**

25. **(Previously Presented)** A compound of claim 2 which is a pharmaceutically acceptable salt of a compound of formula I which is

a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulfonic acid, trifluorosulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; and

b) an acid salt of an organic or inorganic base containing a cation which is an alkaline cation, alkaline earth cation, the ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

26. **(Canceled)**

27. **(Previously Presented)** A pharmaceutical composition comprising a compound of Formula I of claim 2 or a pharmaceutically acceptable salt of a compound of formula I, and a physiologically acceptable carrier.

28. **(Canceled)**

29. **(Cancelled)**

30. **(Canceled)**

31. **(Canceled)**

32. **(Canceled)**

33. **(Canceled)**

34. **(Previously Presented)** A compound which is



















or a pharmaceutically acceptable salt thereof.

35. **(Previously presented)** A pharmaceutical composition comprising a compound which is



















or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier.

36. **(Currently amended)** A method for <u>treating colorectal cancer</u> ~~inhibiting raf kinase~~ in a host , comprising administering to a host in need thereof an effective amount of a compound which is



















or a pharmaceutically acceptable salt thereof.

**37. (Currently Amended)** A compound of Formula I:

A - D - B (I)

or a pharmaceutically acceptable salt thereof, wherein

D is -NH-C(O)-NH-,

A is of the formula: -L-(M-$L^1$)$_q$, where L is phenyl bound directly to D, $L^1$ is pyridinyl, M is oxygen and q is 1; and

B is a substituted or unsubstituted pyridyl, quinolinyl or isoquinolinyl group,

wherein $L^1$ is substituted by -C(O)$R_x$,

$R_x$ is $NR_aR_b$ where $R_a$ and $R_b$ are

independently hydrogen or $C_1$-$C_{10}$ alkyl, ~~$C_1$-$C_{10}$ alkyl, $C_1$-$C_{10}$ alkoxy, $C_{3-10}$ cycloalkyl, $C_{2-10}$ alkenyl, $C_{1-10}$ alkenoyl, $C_{6-12}$ aryl, $C_{3-12}$ hetaryl which is a 5-12 carbon atom aromatic ring system of 1-3 rings, at least one of which is aromatic, in which 1-3 carbon atoms are replaced by heteroatoms selected from O, N and S, 5-6 membered $C_{3-12}$ cycloalkyl having 0-3 heteroatoms selected from N, S and O, substituted $C_{1-10}$ alkyl, substituted $C_{1-10}$ alkoxy, substituted 5-6 membered $C_{3-10}$ cycloalkyl, having 0-3 heteroatoms selected from N, S and O, substituted $C_{6-12}$ aryl, substituted $C_{3-12}$ hetaryl which is a 5-12 carbon atom aromatic ring system of 1-3 rings, at least one of which is aromatic, in which 1-3 carbon atoms are replaced by heteroatoms selected from N, S and O, where $R_a$ and $R_b$ are a substituted group, they are substituted by halogen up to per halo, hydroxy or $C_{1-10}$ alkyl;~~

where B is substituted, L is substituted or $L^1$ is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and Wn, where n is 0-3;

wherein each W is independently -CN, -$CO_2R^7$, -C(O)$NR^7R^7$, -C(O)-$R^7$, -$NO_2$, -$OR^7$, -$SR^7$, -$NR^7R^7$, -$NR^7C(O)OR^7$, -$NR^7C(O)R^7$, $C_1$-$C_{10}$ alkyl, $C_1$-$C_{10}$ alkoxy, $C_2$-$C_{10}$ alkenyl, $C_1$-$C_{10}$ alkenoyl, $C_3$-$C_{10}$ cycloalkyl, phenyl, pyridinyl, pyrazolyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, tetrahydrofuryl, substituted $C_1$-$C_{10}$ alkyl, substituted $C_1$-$C_{10}$ alkoxy, substituted $C_2$-$C_{10}$ alkenyl, substituted $C_1$-$C_{10}$ alkenoyl, substituted $C_3$-$C_{10}$ cycloalkyl substituted phenyl, substituted pyridinyl, substituted pyrazolyl substituted piperazinyl, substituted morpholinyl, substituted piperidinyl, substituted pyrrolidinyl, or substituted tetrahydrofuryl, where W is a substituted group, it is substituted by one or more substituents which are each, independently, -CN, -$CO_2R^7$, -C(O)$R^7$, -C(O)$NR^7R^7$, -$OR^7$, -$SR^7$, -$NR^7R^7$, -$NO_2$, -$NR^7C(O)R^7$, -$NR^7C(O)OR^7$ or halogen,

~~$C_6$-$C_{14}$ aryl, $C_{3-12}$ hetaryl which is a 5-12 carbon atom aromatic ring system of 1-3 rings, at least one of which is aromatic, in which 1-3 carbon atoms are replaced by heteroatoms selected from O, N and S, optionally substituted by one or more substituents which are, independently, -CN, $-CO_2R^7$, $-C(O)R^7$, $-C(O)NR^7R^7$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NO_2$, $-NR^7C(O)R^7$, $-NR^7C(O)OR^7$ or halogen up to per-halo; with each $R^7$ independently $C_1$-$C_{10}$ alkyl, $C_1$-$C_{10}$ alkoxy, $C_2$-$C_{10}$ alkenyl, $C_1$-$C_{10}$ alkenoyl, $C_3$-$C_{10}$ cycloalkyl, $C_6$-$C_{14}$ aryl, $C_{3-12}$ hetaryl which is a 5-12 carbon atom aromatic ring system of 1-3 rings, at least one of which is aromatic, in which 1-3 carbon atoms are replaced by heteroatoms selected from O, N and S, up to per-halosubstituted $C_3$-$C_{13}$ hetaryl which is a 5-12 carbon atom aromatic ring system of 1-3 rings, at least one of which is aromatic, in which 1-3 carbon atoms are replaced by heteroatoms selected from O, N and S, up to per-halosubstituted $C_1$-$C_{10}$ alkyl, up to per-halosubstituted $C_3$-$C_{10}$ cycloalkyl or up to per-halosubstituted $C_6$-$C_{14}$ aryl.~~

**38. (Canceled)**

**39. (Previously Presented)** A compound as in claim 37 wherein the cyclic structures of B and L bound directly to D are substituted in the ortho position by hydrogen.

**40. (Previously Presented)** A compound of claim 37 wherein B of Formula I is a substituted pyridyl, substituted quinolinyl or isoquinolinyl group substituted 1 to 3 times by 1 or more substituents which are each independently -CN, halogen, $C_1$-$C_{10}$ alkyl, $C_1$-$C_{10}$ alkoxy, -OH, up to per halo substituted $C_1$-$C_{10}$ alkyl, up to per halo substituted $C_1$-$C_{10}$ alkoxy or phenyl substituted by halogen up to per halo.

**41. (Canceled)**

**42. (Previously Presented)** A compound of claim 37 wherein $L^1$ is additionally substituted 1 to 3 times by one or more substituents which are each, independently, $C_1$-$C_{10}$ alkyl, up to per halo substituted $C_1$-$C_{10}$ alkyl, -CN, -OH, halogen, $C_1$-$C_{10}$ alkoxy or up to per halo substituted $C_1$-$C_{10}$ alkoxy.

**43 (Canceled)**

**44, (Canceled)**

**45. (Currently amended)** A compound as in claim 37 wherein substituents for B and L and additional substituents for $L^1$, are each, independently, $C_1$-$C_{10}$ alkyl, up to per halo substituted $C_1$-$C_{10}$ alkyl, CN, OH, halogen, $C_1$-$C_{10}$ alkoxy or up to per halo substituted $C_1$-$C_{10}$ alkoxy.

**46. (Previously Presented)** A compound of claim 37 which is a pharmaceutically acceptable salt of a compound of formula I which is

a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluorosulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; and

b) an acid salt of an organic or inorganic base containing a cation which is an alkaline cation, alkaline earth cation, the ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

**47. (Previously presented)** A pharmaceutical composition comprising a compound of claim 37 or a pharmaceutically acceptable salt of a compound of formula I, and a physiologically acceptable carrier.

**48. (cancelled)**

**49. (cancelled)**